Acute myeloid leukemia
Conditions
Interventions
Study Group:HHT 2mg/m2, ivgtt, d6-d10
Sponsors
Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Institute of Hematology
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed AML patients by both morphology and immunology; 2. Rule out APL by morphology and molecular; 3. Rule out MDS history and secondary AML; 4. To be aged 18~55 years; 5. Liver and renal function: serum bilirubin<=35umol/L, AST/ALT lower than 2* upper normal serum level, creatinine<=150umol/L; 6. Normal cardiac function: NYHA I/II; 7. Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2; 8. Signed written informed consent.
Exclusion criteria
Exclusion criteria: 1. APL, previous MDS history, treatment related AML; 2. Previously treated patients; 3. Allergy to any medication in the regimen; 4. Contraindication to anthracyclines; 5. Liver and renal insufficiency (beyond the inclusion criteria); 6. Heart failure NYHA III/IV, severe arrhythmia and myocardial infarction; 7. Patients with a "currently active" second malignancy; 8. Patients with "currently active" tuberculosis. Patients with HIV; 9. Patients with other hematological disease; 10. Patients with pregnancy or lactation; 11. Patients who can't understand or obey the protocol; 12. Patients with a history of intolerance or allergy to the same kind of medication in the regimen; 13. Patients aged beyond 18~55 years; 14. Patients participated in other clinical trial; 15. Other circumstance that obstructs the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival;Relapse Free Survival;Complete Remission Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Early Death Rate;Toxicity and Safety;Minimal residual disease; | — |
Countries
China
Contacts
Public ContactJunmin Li
Outcome results
None listed